Agenda

CONFERENCE DAY 1
Thursday, 11 October 2018
CONFERENCE DAY 2
Friday, 12 October 2018

Registration & Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Keynote: Future of Pharma

Keynote: Innovation from Europe for Europe – Breaking the Vicious Cycles of Eye Disease with a New Turn

Presented by Novaliq

Presented by Novaliq

Networking & Refreshments in Exhibition Hall

Physicians Panel: Testing Innovative MR Methodology With Physicians

Delving into doctor - market researcher interactions and relationships.

Hear insights from a group of physicians that have recently participated in primary market research via TDIs, IDIs, FGDs or on-line surveys and interviews.

Presented by Lifescience Dynamics

Presented by Lifescience Dynamics

Keynote Panel: Reaction/Response to Keynote Presentations

Presented by Actelion, Johnson & Johnson, GlaxoSmithKline, H. Lundbeck A/S, Eli Lilly and Company, Merz Pharmaceuticals GmbH, MSD, Teva Pharmaceuticals, and UCB

Presented by Actelion, Johnson & Johnson, GlaxoSmithKline, H. Lundbeck A/S, Eli Lilly and Company, Merz Pharmaceuticals GmbH, MSD, Teva Pharmaceuticals, and UCB

Networking Luncheon

SESSION ONE

Patient Centricity in Market Research: From Aspiration to Reality

Presented by UCB

Presented by UCB

SESSION TWO

Everything You Always Wanted to Know About Innovation in Market Research (But Were Afraid to Ask)

Presented by Bayer

Presented by Bayer

SESSION ONE

Brand Improv: Be Compliant, But Be Dramatic

Under GDPR, audio and video recordings of research respondents are considered personally identifying information.

So how can researchers continue to leverage the emotional depth of media assets without running afoul of strict privacy controls? One answer is Brand Improv. Brand Improv uses professional actors to reenact real scenarios uncovered in fieldwork. This case study shows how Brand Improv powerfully brings to life new patient and caregiver insights in ADHD.

Presented by M Health

Presented by M Health

SESSION TWO

The Doctor Will See You Now

AplusA initiated a research in the UK and in France to understand current and future challenges faced by the primary

care community, including those pertaining to digital healthcare platforms and their expected impact on their profession, both positive and negative.

Presented by AplusA

Presented by AplusA

SESSION ONE

How to Position a New Anesthetic/Sedative in Market Research

Presented by PAION AG

Presented by PAION AG

SESSION TWO

iAdBoard 2.0: A New Online Solution for Traditional MR

• Introduction to online MR platforms

• What type of MR projects are best suited for online solutions?
• Case studies on different qualitative MR projects executed with iAdBoard: from payer research to competitive tracking

Presented by Lifescience Dynamics

Presented by Lifescience Dynamics

Networking & Refreshments in Exhibition Hall

SESSION ONE

Predictive Modeling – The Future of Tracking

Tracking research is one of the cornerstones of pharmaceutical research, but too often the findings fail to be used to their fullest extent – to inform clients where to act, and what the impact of action is likely to be.

This paper proposes a predictive modelling and advanced analytics framework, leveraging machine learning and automation principles to assess past trends (tracking results) and deliver forward-looking insight at scale. The result is enhanced understanding, and the ability for sales and marketing teams to identify which actions will have the greatest impact on brand performance, leading to more actionable brand management.

Presented by Cello Health Insight

Presented by Cello Health Insight

SESSION TWO

How to Capture Rare Disease ‘Moments-Of-Truth’ Using Online Communities

Market research online communities (MROCs) are growing in popularity because they offer specific benefits over or alongside more traditional methodologies.

Used properly, moderated far-ranging discussions can illicit deep and intimate responses, allowing us to capture those critical “moments of truth”. One of the key benefits in using MROCs is the ability to reach and engage with hard-to-reach respondents such as patients with rare diseases. In cases like this, MROCs provide an opportunity for patients with limited access to support groups to engage with each other, delivering richer insights as a result. During this paper will we demonstrate how, with careful set-up and management, online communities can be excellent methods of attaining an in-depth, meaningful understanding of patients with rare diseases.

Presented by Research Partnership

Presented by Research Partnership

SESSION ONE

Measurement of Business Impact of Insights

Presented by Actelion, Bluefish Pharmaceuticals, Boehringer Ingelheim, Jazz Pharmaceuticals, and Orthogen

Presented by Actelion, Bluefish Pharmaceuticals, Boehringer Ingelheim, Jazz Pharmaceuticals, and Orthogen

SESSION TWO

Hunting Consumer Insights: Approaches and Techniques

Presented by Bluebird Bio, Nano Repro AG, Paedi Protect AG, and Roche

Presented by Bluebird Bio, Nano Repro AG, Paedi Protect AG, and Roche

Evening Socializing & Networking Reception in Exhibition Hall

Registration & Networking Breakfast in Exhibition Hall

SESSION ONE

Big Data – Real Time Targeted Insights

Presented by Sanofi

Presented by Sanofi

SESSION TWO

Market Insights and Forecasting for Cell and Gene Therapies, a Manufacturer’s Perspective

Cell and Gene Therapies are seen as the next frontier in medicine, they have the potential to bring potential cures to patients that suffer from life-threatening diseases without many treatment options available.

The idea that a patient’s own cells can be reprogrammed to attack cancer cells or viruses can be used to repair faulty genes is a paradigm shift in medicine. However, a key challenge for all players and drug-makers in this field remains: significant cost of manufacturing, high price tags and the uncertainty around the market acceptance and uptake make it hard to forecast the potential of these innovative therapies. In this presentation, Fatma Aybegum Senkesen will introduce the audience to the basics of the science behind these therapies and also review how both conventional and innovative methods can be utilized to project the future of this innovative market.

Presented by Lonza

Presented by Lonza

SESSION ONE

Death, Denial, Health and Joy: How Implicit Approaches Reveal Fundamental Changes at the Digital Touch Points Towards Patients and Doctors and How This Affects the Overall Communication Strategy of a Pharmaceutical Brand

Presented by eye square

Presented by eye square

SESSION TWO

(Wo)men vs. Machine - from Competition to Collaboration

Presented by SKIM

Presented by SKIM

Networking & Refreshments in Exhibition Hall

Networking Round Tables Session 1

ROUND TABLE 1
Behavioral Economics Applications to Market Research
Presented by Ferring Pharmaceuticals

Presented by Ferring Pharmaceuticals

ROUND TABLE 2
Competitive Intelligence by Market: How to Tailor and Adjust Your Expansion Strategy
Presented by Nano Repro AG and Paedi Protect AG

Presented by Nano Repro AG and Paedi Protect AG

ROUND TABLE 3
Sample and Survey vs Search and Scrape

Consumer market research is moving to gain more and more insights from consumer activity on the internet (not withstanding GDPR and Cambridge Analytical).

Is pharma is different? Can we gain insights into patients and physician from the internet? Are they a representative sample who can we answers our key business questions?

Presented by Boehringer Ingelheim

Presented by Boehringer Ingelheim

Networking Round Tables Session 2

ROUND TABLE 4
What is the Best Data Strategy to Respond to the Increasing Need for Faster and Cheaper Customer Insights? How to Get Organizations to Recognize the Value of and Acting Upon Such Strategy
Presented by GlaxoSmithKline

Presented by GlaxoSmithKline

ROUND TABLE 5
Social Media - An Opportunity and a Challenge
Presented by Abbott

Presented by Abbott

ROUND TABLE 6
Title TBA
Presented by Gilead

Presented by Gilead

Networking Luncheon

Announcement of Raffle Prize Winners

Summary & Key Takeaways

Presented by Actelion, Johnson & Johnson, GlaxoSmithKline, H. Lundbeck A/S, Eli Lilly and Company, Merz Pharmaceuticals GmbH, MSD, Teva Pharmaceuticals, and UCB

Presented by Actelion, Johnson & Johnson, GlaxoSmithKline, H. Lundbeck A/S, Eli Lilly and Company, Merz Pharmaceuticals GmbH, MSD, Teva Pharmaceuticals, and UCB

Conference Concludes